Stanley Laman Group Ltd. Purchases Shares of 28,125 Gritstone Oncology Inc (NASDAQ:GRTS)
Stanley Laman Group Ltd. purchased a new stake in Gritstone Oncology Inc (NASDAQ:GRTS) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 28,125 shares of the company’s stock, valued at approximately $313,000. Stanley Laman Group Ltd. owned about 0.08% of Gritstone Oncology as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also bought and sold shares of the business. Marshall Wace North America L.P. purchased a new stake in Gritstone Oncology in the first quarter valued at $84,000. D. E. Shaw & Co. Inc. purchased a new stake in Gritstone Oncology in the fourth quarter valued at $157,000. FMR LLC boosted its holdings in Gritstone Oncology by 0.5% in the first quarter. FMR LLC now owns 2,919,381 shares of the company’s stock valued at $38,827,000 after purchasing an additional 15,551 shares during the last quarter. Deutsche Bank AG purchased a new stake in Gritstone Oncology in the fourth quarter valued at $448,000. Finally, Northern Trust Corp purchased a new stake in Gritstone Oncology in the fourth quarter valued at $1,207,000. 57.66% of the stock is currently owned by institutional investors.
Shares of GRTS traded down $0.07 during mid-day trading on Thursday, hitting $9.60. 355 shares of the company were exchanged, compared to its average volume of 114,023. Gritstone Oncology Inc has a 1-year low of $8.75 and a 1-year high of $32.90. The company has a current ratio of 9.57, a quick ratio of 9.57 and a debt-to-equity ratio of 0.13. The firm’s 50 day simple moving average is $10.54. The stock has a market cap of $345.41 million and a PE ratio of -1.33.
Several research firms have recently issued reports on GRTS. Cowen reissued a “buy” rating on shares of Gritstone Oncology in a research note on Monday, May 13th. ValuEngine raised shares of Gritstone Oncology from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research lowered shares of Gritstone Oncology from a “buy” rating to a “hold” rating in a research note on Wednesday, July 17th. Finally, Robert W. Baird began coverage on shares of Gritstone Oncology in a research note on Thursday, July 25th. They set an “outperform” rating and a $17.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $20.00.
Gritstone Oncology Company Profile
Gritstone Oncology Inc, an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.
Featured Story: Understanding Price to Earnings Ratio (PE)
Want to see what other hedge funds are holding GRTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gritstone Oncology Inc (NASDAQ:GRTS).
Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.